Published: Fri, April 21, 2017
Health | By Jay Jacobs

Argos Therapeutics Inc (ARGS) Receives Consensus Recommendation of "Hold" from Brokerages

Consensus earnings estimates are far from flawless, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. The company's institutional ownership is monitored at 17.4 percent. This score is based on the Gross Margin stability and growth over the previous 8 years.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.26 and $-0.39, respectively, according to 2 analysts.

Shares of Argos Therapeutics (NASDAQ:ARGS) traded up 7.73% on Friday, reaching $0.39.

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Zacks Investment Research cut shares of Argos Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, February 7th. The high and low revenue estimates for the current quarter are $150000 and $100000, respectively.

P/E of the company is not reported. Look at the direction of the moving average to get a basic idea of which way the price is moving. The primary efficacy endpoint for the study is a statistically significant improvement in overall survival, with secondary efficacy endpoints evaluated to date of progression-free survival, objective response rate and disease control rate, and an exploratory efficacy endpoint of immune response.

The stock's price switched up -21.46% 20-Days Simple Moving Average, dropped -78.15% from 50-Days Simple Moving Average and fell -90.64% from 200 Days Simple Moving Average. The stock ended last trade at $0.39 a share and the price is up more than -92.02% so far this year.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future. Annual EPS Growth of past 5 years is -3.90%. (ARGS) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 4 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. JMP Securities downgraded shares of Argos Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 22nd. (ARGS) in a note sent to investors on 22-Feb-17. The stock is a Buy among 14 brokerage firms polled by Factset Research. The brokerage now has a "mkt perform" rating on the biopharmaceutical company's stock. The Company also provided perspective on its decision to continue the trial. Additionally, ROTH Capital Initiated its ratings on the stock to Buy. The stock established a positive trend of 75.95% in last week and indicated fall of -29.41% in previous month. Sanders Morris Harris Inc. raised its position in shares of Argos Therapeutics by 109.9% in the third quarter.

Toll Brothers, Inc. (NYSE:TOL), maintained return on investment for the last twelve months at 4.70, higher than what Reuters data shows regarding industry's average.

Like this: